Pharma Mar, S.A.

MCE PHM.MC

Pharma Mar, S.A. Price to Sales Ratio (P/S) on January 14, 2025: 7.75

Pharma Mar, S.A. Price to Sales Ratio (P/S) is 7.75 on January 14, 2025, a 79.83% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Pharma Mar, S.A. 52-week high Price to Sales Ratio (P/S) is 8.56 on November 11, 2024, which is 10.51% above the current Price to Sales Ratio (P/S).
Pharma Mar, S.A. 52-week low Price to Sales Ratio (P/S) is 2.76 on April 19, 2024, which is -64.35% below the current Price to Sales Ratio (P/S).
Pharma Mar, S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 4.91.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

MCE: PHM.MC

Pharma Mar, S.A.

CEO	Mr. Jose Maria Fernandez Sousa-Faro Ph.D.
IPO Date	Sept. 8, 2000
Location	Spain
Headquarters	Avenida de los Reyes, 1
Employees	509
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Key trends

Past 5 years